Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in moderate-to-severe plaque psoriasis
NCT03818035Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in plaque psoriasis (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index Less Than 3 at 68 weeks. Started Feb 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03818035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818035.